Hepatitis C patients will no longer have to undergo treatment for 24 or 48 weeks anymore. Achillion Pharmaceuticals (NASDAQ:ACHN)’s drug ‘ACH-3102’ along with Gilead Sciences (NASDAQ:GILD)’s Hepatitis C drug ‘Sovaldi’ can cure a hepatitis patient within six weeks of treatment. This is indeed big news for Hepatitis C patients where they had to take heavy dosage of multiple drugs for 48 weeks or so and the results weren’t even 100 percent. We must mention that the results from Achillion Pharmaceuticals (NASDAQ:ACHN)’s and Gilead Sciences’ (NASDAQ:GILD)’s drug combination are absolute 100 percent. This is a big breakthrough in medical science and a success for the healthcare industry.
As we have mentioned, the previous drugs prescribed for Hepatitis C patients were not convenient at all. Most of the time, drugs needed to be injected rather than taken as pills. The results were barely satisfactory and the time period was almost a whole year. In such circumstances, it was very painful and demoralizing for the patient, not to mention extremely strenuous on the nerves. But Hepatitis C won’t be haunting us anymore because now it is completely curable and that too within six weeks.
Gilead Sciences (NASDAQ:GILD)’s Sovaldi was a 12 week treatment which was better than the most but not perfect, but now with the association of Achillion Pharmaceuticals (NASDAQ:ACHN)’s ACH-3102 the results will be far better and the patients will be cured within 2 months of time. The best thing about this drug is that it will not be harmful to the patient like the injections. The drug will prove to be a blockbuster on the market, and will surely attract investors from all around. Achillion Pharmaceuticals (NASDAQ:ACHN)’s and Gilead Sciences (NASDAQ:GILD)’s stock is likely to go up whenever the drug hits the market.
Gilead Sciences (NASDAQ:GILD)’s stock has been waning in the past couple of weeks and analysts were forecasting a low 2015. Achillion Pharmaceuticals (NASDAQ:ACHN)’s has come to Gilead Sciences (NASDAQ:GILD)’s rescue and both the companies will benefit from the association. Finding a cure for Hepatitis C which is completely effective and eliminates the disease totally from the patient’s body is indeed a big achievement and for that both these companies deserve accolades. And they are going to get them when the drug makes it to the market, with the approval of the Food and Drug administration department.
There was a lot of room for improvement in Sovaldi and had ACH-3102 not come into the scenario, Sovaldi would have lost its steam and the health industry would have had to replace it with some alternative. But much to the joy of Gilead Sciences (NASDAQ:GILD), that won’t be happening. Sovaldi and ACH-3102 will make history in the healthcare industry and will subjugate a terrible disease that has cost the lives of many human beings. Hepatitis C is now curable and that too in a record 6 weeks and that is indeed good news for the industry and both of these companies.
